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Abstract
Repeat lengths of the CAG and GGN micro-satellites in exon 1 of the androgen receptor (AR) gene
have been hypothesized to be associated with prostate cancer risk. In vitro studies have showed an
inverse association between AR CAG and GGN repeat length and activity levels of the AR product.
It is known that men of African descent have a higher incidence of and greater mortality from prostate
cancer than men of Caucasian or Asian descent and, on average, a smaller number of repeats at AR
CAG and GGN. Consistent with these findings, studies have also found increased AR protein
expression levels in benign prostatic hyperplasia and prostatic diseased tissues from men of African
descent. Despite these findings, limited studies have been conducted to evaluate the association
between repeat lengths at AR CAG and prostate cancer risk in African Americans. Our study is the
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first such study to examine whether repeat length of the AR GGN repeat is associated with prostate
cancer risk in African Americans. We found no evidence for an association between AR CAG or
GGN repeat lengths and prostate cancer risk in a population-based sample of African Americans.
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Introduction
In 2006, prostate cancer was the most commonly diagnosed non-skin cancer among men in
the United States, with an estimated 218,890 new cases, and a leading cause of cancer-related
mortality, with an estimated 27,050 related deaths (Jemal et al. 2007). Increasing age, positive
family history and African ancestry are known risk factors for prostate cancer (Bostwick et al.
2004).
The clustering of prostate cancer cases among families has motivated the search for genetic
risk factors for the disease. One of the most studied genes implicated in prostate cancer
susceptibility is the androgen receptor (AR) gene on chromosome Xq11–12. The AR gene
product regulates expression of the genes necessary for growth and development of many target
tissues, including male reproductive organs. Variant forms of two different microsatellite
polymorphisms [the polyglutamine (CAG)n repeat and the imperfect polyglycine (GGN)n
repeat, both located in exon 1 of AR] have been shown to alter the biological function of the
AR gene and consequently have been hypothesized to modify the risk for developing prostate
cancer. Specifically, in vitro studies (Beilin et al. 2000; Chamberlain et al. 1994; Kazemi-
Esfarjani et al. 1995; Tut et al. 1997; Ding et al. 2004; Ding et al. 2005) have demonstrated an
inverse relationship between the length of both repeats and AR activity levels. The recent article
by Rajender et al. (2007) provides a nice review on the AR CAG and GGN repeats with respect
to their function and their statistical association with a wide range of clinical phenotypes.
Studies comparing the distribution of allele sizes for the CAG and GGN microsatellite repeat
polymorphisms between different populations have noted shorter repeat lengths, on average,
in men of African versus Caucasian descent (Kittles et al. 2001; Esteban et al. 2006). Consistent
with the in vitro studies showing increased activity of the AR product with shorter AR CAG
and GGN repeat alleles, studies have also found increased AR protein expression levels in
prostatic tissues from men of African descent (Gaston et al. 2003; Olapade-Olaopa et al.
2004). Specifically, AR protein expression levels were estimated to be 22% higher in benign
prostate cancer tissues and 81% higher in malignant prostate cancer tissues in African
Americans versus Caucasian Americans (Gaston et al. 2003).
Through a literature search, we have identified over 30 studies that have evaluated the
association between the AR CAG and GGN repeats and prostate cancer. Results from many of
these studies have been summarized in a meta-analysis (Zeegers et al. 2004). These studies
have focused primarily on men of Caucasian descent. Typical of genetic association studies
for complex traits, the results from these studies have varied considerably. Taken together, the
cumulative results across these different studies suggest that if there is an effect of short alleles
at the AR CAG and GGN repeats on prostate cancer risk, then the magnitude of the differential
risk, at least in Caucasian men, is likely small.
African-American men have an approximately 1.6-fold greater chance of being diagnosed with
prostate cancer compared to Caucasian men and a 2.4-fold greater chance of dying from the
disease (Jemal et al. 2007). In addition, African-American men are more frequently diagnosed
with higher tumor volume, more advanced tumor stage, higher Gleason grade and higher
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prostate-specific antigen levels (Brawn et al. 1993; Vijayakumar et al. 1998; Fowler and Bigler
1999; Moul et al. 1999; Powell et al. 1999; Fowler et al. 2000; Thompson et al. 2001). These
findings have suggested that prostate cancer in African-American men may involve different
etiological factors and may be more biologically aggressive. Given the strong genetic
heterogeneity of prostate cancer, different levels of background risk factors and plausibly
unique genetic and environmental interactions, it is important to study the effects of AR CAG
and GGN repeat lengths on prostate cancer susceptibility directly in African-American men
rather than relying on results from extensive studies in Caucasian men.
Unfortunately, despite their increased risk for developing the disease, very limited studies
regarding the risk of these AR repeat polymorphisms on prostate cancer in African Americans
have been conducted. A small study on 20 men of African descent diagnosed with prostate
cancer and 20 healthy controls found no evidence for an association between AR CAG allele
size and prostate cancer risk (Panz et al. 2001). Similarly, a study on 118 African-American
men diagnosed with prostate cancer and 567 African-American controls revealed no evidence
for an association between AR CAG repeat length and prostate cancer (Gilligan et al. 2004).
A multiethnic cohort study with 635 African-American prostate patients and 664 African-
American controls also failed to identify any association between AR CAG repeat length and
prostate cancer (Freedman et al. 2005).
Herein, we evaluate the association between the AR CAG and AR GGN repeat polymorphisms
and prostate cancer in a community-based sample of 471 African- American men from Flint,
Michigan (Cooney et al. 2001). To our knowledge, this is the first study to assess the risk of
the AR GGN repeat on prostate cancer in African-American men. We found no evidence to
support the association between either the AR CAG or AR GGN repeat polymorphisms and
prostate cancer in this population.
Materials and methods
Subjects
African-American subjects from this study were part of the Flint Men’s Health Study (FMHS)
(Cooney et al, 2001). The FMHS is a community-based study of prostate cancer in African-
American men between the ages of 40 and 79 years. In 1996, 730 men were recruited to
participate in the study from a probability sample residing in the city of Flint and surrounding
communities in Genesee County, Michigan. Subjects completed a detailed in-home interview
that collected information on socio-demographics, potential risk factors for prostate cancer and
a complete medical history. Subjects were also asked to participate in a clinical examination
that included measurement of serum PSA (free and total) and a comprehensive urologic
examination. Men with an elevated total PSA (>4.0 ng/ml) or an abnormal digital rectal exam
were referred for prostate biopsy. Of the 730 men who completed the initial interview, 379
participated in the clinical exam. A total of ten subjects were diagnosed with prostate cancer
as a consequence of the protocol, which resulted in a final control sample of 369 men. Attempts
were made to follow the study participants, and in the 5 years after control recruitment, an
additional 18 control men were diagnosed with prostate cancer. For this study, a sufficient
DNA sample was available for genotyping on 342 controls.
Cases were recruited from the same community from 1999 to July 2002. Men who were
between the ages of 40 and 79 years at the time of prostate cancer diagnosis (between 1995
and 2002) were eligible to participate in the study. Patients also completed a detailed
epidemiologic interview and provided a blood sample. Medical records were reviewed to
extract information related to prostate cancer diagnosis including clinical and pathologic stage,
Gleason grade, prediagnostic PSA and treatment. A total of 136 patients were ultimately
recruited to participate in the study (including the control men who were diagnosed with
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prostate cancer through participation in the study, n = 10). For this study, sufficient DNA
samples were available for genotyping on 131 cases. Informed consent was obtained from all
study participants, and the research protocol was approved by the Institutional Review Board
of the University of Michigan.
Genotyping
For both cases and controls, genomic DNA was isolated from whole blood using the Puregene
DNA Purification Kit (Gentra Systems, Minneapolis, MN). The number of AR CAG and GGN
DNA repeats was determined by PCR-based fragment analysis, using fluorescently labeled
primers (Roberts et al. 2004). Briefly, each 15 µl reaction contained 15 ng genomic DNA, 2
mM MgCl2, 200 µM dNTPs, 0.67 µM each primers and 0.5 U Amplitaq Gold (Applied
Biosystems, Foster City, CA). The annealing temperatures were 55°C for AR CAG repeats and
58°C for AR GGN repeats. PCR products were resolved on an ABI 3100 DNA sequencer
(Applied Biosystems), each capillary is calibrated using internal reference standards and
control samples were included in each plate to ensure accuracy of genotypes.
Genotype was scored successfully for 130/131 and 129/131 cases for AR CAG and GGN,
respectively. Genotype was scored successfully for both AR CAG and GGN for 340/342
controls; 2 controls did not successfully genotype at either AR CAG or GGN. In total, 131
patients and 340 controls had genotype data available on at least one of the two AR repeats.
Statistical methods
To measure the strength of dependence (of allele size) and linkage disequilibrium between the
CAG and GGN repeats, we calculated Spearman’s correlation coefficient and used Lewontin’s
D′ (Lewontin 1964) modified for multiple alleles (Hedrick 1987) separately for both the case
and control samples. For two-allele markers, D′ is the standardized disequilibrium value that
takes the usual disequilibrium coefficient P(AiBj) − P(Ai)P(Bj) and divides it by its maximal
possible value. Given multiple alleles, we calculate the weighted average of the D′ values where
the weights are the products of the corresponding allele frequencies. That is,
(1)
where pi and qj are allele frequencies at the two loci of interest, and Dij′ is the standardized
disequilibrium coefficient based on alleles Ai and Bj. Statistical significance of the magnitude
of the estimated D′ values was assessed using a permutation test in which, under the null
distribution (i.e., linkage equilibrium), within a sample the alleles at the two repeats were
randomly shuffled between individuals independently.
To evaluate the haplotype diversity in this African-American sample, we constructed the
observed haplotype frequency distribution in the combined sample of 468 men with genotype
data available at both AR CAG and GGN. We determined the median allele size for each repeat
in the combined sample and used these observed medians as allele size thresholds to partition
the haplotypes from the complete sample into four groups based on allele size combinations
at the two repeats. We then performed an additional test of independence of allele sizes at the
two repeats by calculating the expected number of haplotypes for each of the four groups and
used a Pearson’s chi-square test to evaluate whether the observed number of haplotypes in each
group was consistent with the expected numbers.
We used unconditional multivariable logistic regression models to assess the association
between AR CAG and GGN repeat lengths and prostate cancer. Two levels of covariate
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adjustment were made to all models: (1) age only and (2) age and estimated proportion of
African ancestry. Approximately half of the FMHS control men were tested at multiple time
points for prostate cancer. To avoid lead-time bias in the multivariable analyses, age was
calculated based on the same date for all cases and controls. This date was the most recent
follow-up date from the entire sample, with the exception that age at death was used for the 37
controls that died prior to this date. Estimated proportion of African ancestry for each study
participant had been obtained previously (Amundadottir et al. 2006) using the statistical
software Structure (Pritchard 2000). AR CAG and GGN repeat length were analyzed as both
continuous measures or dichotomized based on repeat length thresholds previously suggested
in the AR-prostate cancer literature (two cut-off values were considered for CAG: ≤21 vs. >21
and ≤22 vs. >22 and one cut-off value for GGN: ≤16 vs. >16). We analyzed the effects of CAG
and GGN repeats separately and jointly. In addition, we tested for interaction effects between
the AR CAG and GGN repeats on prostate cancer risk. Finally, t tests were used to assess
statistical significance of observed differences in means for age and estimated proportion of
African ancestry between cases and controls. All analyses were performed using the SAS,
version 9.1.3, statistical software package (SAS Institute, Cary, NC), and all tests, unless
otherwise stated, were evaluated using a two-sided hypothesis test.
Results
The total sample consisted of 471 (131 prostate cancer cases, 340 disease-free controls)
African-American subjects. Mean age overall was 63.5 years (standard deviation or SD = 10.0)
with patients being older than controls (patient mean age = 67.2 years, SD = 8.6; control mean
age = 62.1 years, SD = 10.1; P<0.0001). A family history of prostate cancer in a first-degree
relative was reported by 21.4% of the patients and 17.0% of the controls. Based on the definition
from the International Consortium for Prostate Cancer Genetics (Schaid et al. 2006), 72.5% of
the patients were assessed to have clinically aggressive prostate cancer. Sixty percent of cases
had cancers with a Gleason score of 7, and 11% had cancers with a Gleason score ranging from
8 to 10. There was no statistical difference in mean proportion of African descent between
cases (mean proportion = 0.705, SD = 0.077) and controls (mean proportion = 0.707, SD =
0.077).
The observed allele frequencies for cases and controls for AR CAG and GGN are presented
graphically in Fig. 1 and Fig.2, respectively. The average number of repeats was similar for
cases and controls for both the AR CAG (case mean = 19.92, SD = 3.37, median = 19; control
mean = 19.91, SD = 3.47, median = 20) and GGN (case mean = 15.76, SD = 2.10, median =
16; control mean = 15.41, SD = 2.22, median = 16) polymorphisms. AR CAG and GGN repeat
lengths were significantly negatively correlated in both cases (Spearman’s correlation = −0.17,
P = 0.05) and controls (Spearman’s correlation = −0.17, P = 0.002), indicating that shorter
repeats for AR CAG are on haplotypes containing longer GGN repeats, and visa versa, in this
population. Consistent with these findings, AR CAG and GGN were found to be in significant
linkage disequilibrium in both cases (estimated D′ = 0.55, P<0.0001) and controls (estimated
D′ = 0.41, P<0.0001).
A total of 112 distinct haplotypes were observed among our complete sample of 468 men with
genotype data on both AR CAG and GGN, with the haplotype defined by AR CAG = 18 and
GGN = 17 the most common observed haplotype (frequency = 0.058). Only 11 different
haplotypes were observed more than ten times each, while 41 haplotypes were observed just
once. We observed 129 (CAG ≤ 20, GGN ≤ 16), 122 (CAG ≤ 20, GGN > 16), 164 (CAG >
20, GGN ≤ 16) and 53 (CAG > 20, GGN > 16) haplotypes in groupings based on the observed
median repeat length values of AR CAG (median = 20) and GGN (median = 16). Consistent
with the observed negative correlation between allele lengths at AR CAG and GGN, these
observed counts were significantly different than the expected number of haplotypes in these
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groupings (157, 94, 136 and 81, respectively) under the null hypothesis of independence
(P<0.0001).
Results from the logistic regression models are presented in Table 1. Age was a significant risk
factor for prostate cancer (P < 0.0001) in all models. Estimated proportion of African descent
was not a significant risk factor in any models and, as demonstrated in Table 1, modified the
observed effects of genotype negligibly. No evidence for an association between AR CAG
repeat lengths and prostate cancer was detected when modeling AR CAG repeat length as a
continuous variable or as a dichotomous variable with allele cutoff thresholds of ≤21 and ≤22
repeats, after adjustment for age or age and estimated proportion African ancestry. Similarly,
no statistically significant association was found between AR GGN repeat length and prostate
cancer regardless of whether GGN repeat length was treated as a continuous measure or as a
dichotomous variable defined by an allele cutoff threshold value of ≤16 repeats. Given the a
priori hypothesis that shorter alleles at both AR CAG and GGN increase risk for prostate cancer,
we get a suggestive one-sided P value (P = 0.055) when using a cutoff threshold of ≤22 repeats
for AR CAG. Applying a similar one-sided hypothesis test to AR GGN would result in a
decreased estimate of statistical significance (versus the two-sided test) given that we observed
modestly longer repeat lengths for AR GGN among cases. Modeling AR CAG (≤22 vs.>22)
and GGN (≤16 vs.>16) jointly reduced the estimated significance for CAG modestly (P = 0.18).
No evidence for a significant interaction between AR CAG and GGN was detected (P = 0.49).
Finally, we found no evidence for an association with prostate cancer when evaluating men
with AR CAG ≤22 and GGN ≤16 (P = 0.47) or men with AR CAG ≤22 or GGN ≤16 (P = 0.42).
Discussion
Our results, from a population-based sample of 131 African-American men diagnosed with
prostate cancer and 340 screened African-American male controls, showed no significant
evidence of an association between shorter alleles at AR CAG or GGN and increased risk of
prostate cancer. In fact, we observed modestly longer GGN repeat lengths among our cases.
Our data, combined with three previous reports, suggest that the observation of shorter alleles
at AR CAG in African Americans does not significantly account for increased prostate cancer
risk in African Americans and does not appear to explain the difference in incidence of the
disease between men of African and Caucasian descent. Our study is the first study to evaluate
the effect of allele length for AR GGN on prostate cancer risk in African Americans. Our
findings suggest that a shorter number of repeats at AR GGN do not have a major effect on
prostate cancer susceptibility. Clearly larger studies on African Americans will be necessary
to have sufficient power to conclusively evaluate whether there are any mild effects of the
AR CAG and GGN polymorphisms on prostate cancer risk in this population.
The AR CAG and GGN repeats are only 1,176-bp apart (for a CAG repeat length of 22 repeats),
suggesting these two microsatellites are likely to be in linkage disequilibrium or LD (Salinas
et al. 2005). Kittles et al. (2001) noted increased haplotype diversity for these repeats in
individuals of African descent and computed pair-wise estimates of LD for all possible
combinations of allele sizes at the two repeats. Their results suggested that the allele lengths
at these repeats are not independent in African populations, but that there was no evidence of
LD in the other populations considered (though it should be noted that sample sizes were
considerably smaller for the other populations). Given the pair-wise analytic strategy, it was
difficult to determine whether there was any consistent pattern of shorter alleles at one repeat
being associated with longer alleles at the other. Hsing et al. (2000) found no evidence for any
correlation between allele sizes at the two repeats in a sample of 190 prostate cancer cases and
304 controls from China (Spearman’s correlation = −0.03, P > 0.05), and Salinas et al.
(2005) reported no evidence for LD in a sample of 455 Caucasian controls (D′ = 0.11).
However, some evidence for a negative correlation between allele sizes at these two repeats
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has been reported (Irvine et al. 1995; Correa-Cerro et al. 1999; Chang et al. 2002). In the largest
of these studies, Chang et al. (2002) found strong evidence for LD (P = 0.0003) in a sample
of approximately 350 unrelated Caucasian sporadic prostate cancer cases and controls. To
summarize, the evaluation of LD between these two AR microsatellites has not been performed
using uniform methodology across studies, and it is therefore difficult to evaluate the direction
and overall significance of LD between these two repeats in African Americans as well as other
racial groups. We have performed an extensive analysis of haplotype structure and LD between
AR CAG and GGN repeats in our African-American sample and found considerable haplotype
diversity in this sample and strong evidence for a negative correlation between allele sizes at
the two repeats. One implication of these findings is that results, at least in African Americans,
from association studies using AR CAG and GGN repeat lengths are not independent and that
future studies should consider modeling the effects of the two repeats jointly in addition to
analyzing their effects individually.
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